Multilineage-differentiating Stress-Enduring (Muse) Cells™ are a distinct population of adult-derived stem cells discovered by Professor Mari Dezawa.
Unlike conventional MSCs, which act primarily through paracrine signaling, Muse Cells™ are naturally pluripotent, stress-resilient, and capable of spontaneous in vivo differentiation into all three germ layers—without genetic reprogramming or chemical induction.
This enables direct regeneration of functional tissue across multiple organ systems, with an exceptionally low risk of tumorigenicity.
In 2010, Professor Mari Dezawa and her team at Tohoku University identified a rare, stress-resilient subpopulation of adult stem cells—now known as Dezawa MuseCells®.
What makes them different?
Spontaneous trilineage differentiation
Dezawa MuseCells® generate ectoderm, mesoderm, and endoderm lineages in vivo—without reprogramming or induction, and without teratoma formation.
Survival under extreme stress
They remain viable where most cells fail, including serum deprivation and oxidative stress (ROS exposure).
Embryonic marker expression without instability Dezawa MuseCells® express SSEA-3, a marker associated with embryonic stem cells, yet maintain a stable karyotype and low telomerase activity—even under stress.
With over 85 peer-reviewed studies and 120+ publications—including Phase II trials in Japan—Dezawa MuseCells® are supported by one of the most substantial evidence bases in regenerative medicine. Licensing offers partners exclusive access to this rigorously defined and validated platform.
Defined, patented, and validated in more than a decade of peer-reviewed research—Dezawa MuseCells® represent a trusted platform in regenerative medicine.
All published information utilizes Dezawa MuseCells® that are manufactured in accordance with MCIs patented processes.
Research results apply only to Dezawa MuseCells® manufactured under Muse Cell Innovations®’ patented methods.
Claims are based on published studies of Dezawa MuseCells® made under Muse Cell Innovations®–licensed methods; results cannot be assumed for products manufactured differently.
Dezawa MuseCells® are the first and only MSC therapy that convinces clinicians and scientists alike because of its safety and efficacy. What the field has been waiting for more than 30 years, finally a stem cell treatment that works.
Dezawa MuseCells® detect S1P—a lipid released by injured tissue—and migrate directly via S1PR2 receptors. This active targeting distinguishes them from MSCs, which become passively trapped (e.g., in the lungs).
HLA-G⁺ inhibits NK and cytotoxic T-cell activation, enabling allogeneic (donor-based) use without immunosuppression.
SSEA-3 is a surface marker of pluripotent capability. Enriching for SSEA-3⁺ ensures the product is consistent, traceable, and therapeutically relevant.
This gene profile supports pluripotency without tumor risk. Let-7 suppresses oncogenic pathways; Lin28 is downregulated, reducing malignancy potential.
Dezawa MuseCells® show low telomerase, reducing risk of uncontrolled proliferation compared to iPSCs or ESCs.
Dezawa MuseCells® exhibit a stable chromosomal profile, even in long-term cultures—a key safety requirement for clinical-grade cell banking.
Unlike MSCs, Dezawa MuseCells® engulf apoptotic cells at the injury site—triggering spontaneous in vivo differentiation into functional tissue.
See how they migrate, repair, and restore function in real models.
